CN101269152A - Application of matrimony vine and black fungus in preparing fatty liver resistant medicament - Google Patents
Application of matrimony vine and black fungus in preparing fatty liver resistant medicament Download PDFInfo
- Publication number
- CN101269152A CN101269152A CNA200710038186XA CN200710038186A CN101269152A CN 101269152 A CN101269152 A CN 101269152A CN A200710038186X A CNA200710038186X A CN A200710038186XA CN 200710038186 A CN200710038186 A CN 200710038186A CN 101269152 A CN101269152 A CN 101269152A
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- liver
- group
- granule
- auricularia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the foodstuff and health product field, in particular relates to an application of the traditional Chinese medicine of medlar and blackfungus to the preparation of a drug for curing fatty liver. The invention adopts a medlar and blackfungus compound granular formulation. The fat emulsion made of fat, cholesterin, sodium taurocholate and propylthiouracil is given to rats; a fatty liver animal model is made; the function for preventing fatty liver of medlar and blackfungus is studied. The experimental results show that the medlar and the blackfungus have evident functions for preventing fatty liver and can reduce the liver weight/body mass index, the contents of serum and hepatic tissue cholesterin are decreased and the number of liver cells of steatosis is reduced. The medlar and the blackfungus can be used for preparing the drug for curing fatty liver.
Description
Technical field
The present invention relates to the application in preparation anti-fatty liver medicine of Fructus Lycii and Auricularia.
Background technology
Lipid content accounts for the 2%-4% of liver weight in wet base in normal person's the liver, and wherein phospholipid accounts for more than 50%, and triglyceride (TG) accounts for 20%, and free fatty (FFA) accounts for 20%, and cholesterol accounts for 7%, and all the other are cholesteryl ester.When the hepatocyte inner lipid is accumulated above 5% of liver weight in wet base, or the histology is when going up per unit area 1/3 above hepatocyte fat change being arranged, be called fatty liver (Zhang Darong. fatty liver. Shanghai medicine, 1995,4 (7): 56-57).
Fatty liver is meant the disease of the excess fat that causes because of the outer reason of liver itself and liver due to gathering lastingly in liver, its cause of disease mainly contains due to excessive drinking, obesity, diabetes, gestation, hepatitis and medicine (as 17-hydroxy-11-dehydrocorticosterone) or the poisonous substance liver injury.Primary disease belongs to that Chinese medicine " is gathered " and " wet resistance " category.Common sympton has: the liver enlargement, and hepatalgia or discomfort, loss of appetite, gastral cavity abdomen painful abdominal mass expands, loose stool, minority can have slight yellow cellulitis.Also have or not obvious clinical symptoms person.
According to statistics, the sickness rate of fatty liver accounts for 10% of population, 50% of obesity and diabetics, 57.5% of alcoholic, and no matter be ethanol or non-alcoholic fatty liver disease, the hepatic fibrosis incidence rate is up to 25%, the patient of about 1.5%-8.0% can develop into liver cirrhosis (model is built high. the Progress in Medication of fatty liver. Chinese hepatopathy magazine, 1996,4 (4): 28-29).
Active drug to the fatty liver treatment on the current market comprises: choline, and methionine, inositol, simvastatin etc., though they have therapeutical effect preferably to fatty liver, taking itself for a long time also is a kind of burden to liver, and price is also quite expensive.
Non-alcoholic fatty liver disease (NAFL) is a kind of no excessive history of drinking history, and hepatic parenchymal cells steatosis and fat are stored up the clinical pathology syndrome for feature.Spectrum of disease differs with the progress performance of the course of disease, comprises simple fatty liver, fat hepatitis (NASH), fatty liver fibrosis and 4 histological type of fatty liver cirrhosis.Clinical epidemiology studies show that, NAFL accounts for 10%-24% general crowd, in the overweight people, account for 57.5%-74%, there is the patient of 12%NASH that hepatitis interstitialis chronica takes place every year on average, 8% can make progress to hepatitis interstitialis chronica causes a series of severe complications, NASH be considered to the latent cirrhotic commonly encountered diseases of source property because of.Therefore, the control of NASH is expected to stop chronic hepatopathy progress, improve fatty liver prognosis (Xiao Wenbin etc. non-alcoholic hepatitis research progress. clinical liver-gallbladder disease magazine, 2001,17 (2): 71-73).
Modern pharmacology to Chinese medicine lipotropic research done a large amount of work, mainly comprise single medicinal material and study of compound prescription two aspects.
Single medicinal material: Radix Ginseng, the oral rising to hypercholesterolemia (CH) diet rat blood serum T-CHOL (TC), triglyceride (TG) of Radix Ginseng powder all has obvious reduction effect; Radix Polygoni Multiflori, Radix Polygoni Multiflori powder can make that TG, TC reduce by 89% and 42% respectively in the high fat animal blood, liver TG reduce by 52% (Ye Jun. the lipotropic progress of single medicinal material. Shandong journal of Chinese medicine, 1995,14 (7): 331-331).
Study of compound prescription: Li Chuanfu etc. are to the side's of plan lipid level (Radix Polygoni Multiflori certainly, medicines such as Pollen Typhae composition) experimentation shows, this can reduce effectively liver cholesterol and the triglyceride of hyperlipidemia rats and rabbit level (Liu Yanling. brief talk the Chinese medicine of fatty liver. Beijing University of Chinese Medicine's journal, 1995,18 (5): 54-55).
Fatty liver is as the middle pathological process of hepatic disease, at viral hepatitis, drug intoxication hepatitis, insobriety, and all can take place during obesity.If pathological changes in time take adequate measures in early days, the pathological change of fatty liver is reversible.The food that it has been generally acknowledged that high food fiber, homomethionin, high phosphorus lipid and be rich in vitamin A has lipotropic effect (Takase S.Enyama K.Takada A etal.Effects of vitamin A on collagen metabolism by cultured ratcells.Gastroenterol Jpn, 1992:27 (3): 354-354).For example, have data think Folium Camelliae sinensis have blood fat reducing effect (Qiu Donglian. Folium Camelliae sinensis and cardiovascular and cerebrovascular disease. tea newspaper, 1992,9 (3): 41-42).
Therefore, extract active component from the Chinese medicine of medicine-food two-purpose, by oral, whether observation has blood fat reducing and plays the effect of control fatty liver, explores for excavating effective, practical control fatty liver medicine.
Summary of the invention
Technical problem to be solved by this invention provides Chinese medicine Fructus Lycii and the new purposes of Auricularia in pharmacy.
The present invention relates to Chinese medicine Fructus Lycii and the Auricularia purposes in preparation anti-fatty liver medicine.
The Chinese medicine Fructus Lycii that the present invention relates to and the above-mentioned effect of Auricularia and purposes does not see that relevant report is arranged.
Fructus Lycii involved in the present invention and Auricularia use the granule of its compositions.
Fructus Lycii involved in the present invention is the dry mature fruit of plant of Solanaceae lycium barbarum Lycium barbarum L.; Auricularia is mushroom food Auricularia auricular-judae.
Fructus Lycii involved in the present invention was gathered when fruit is orange red in summer, two season of autumn, dried in the air to rhicnosis, tan by the sun again stiff to crust, sarcocarp is soft, removes carpopodium; Or the hot blast oven drying at low temperature, remove carpopodium.
Fructus Lycii involved in the present invention is the class spindle, and is slightly flat, long 6-21mm, diameter 3-10mm.Surface cerise or kermesinus, top have the stylar scar of small embossment volt, the carpopodium trace of base portion adularescent.Peel is pliable and tough, shrinkage; The sarcocarp meat, soft and moist and toughness, the seed majority, class kidney shape is flat and stick up long 1.5～1.9mm, wide 1～1.7mm, the light yellow or pale brown color in surface.Odorless, sweet, little acid of distinguishing the flavor of.
The preparation process of above-mentioned Fructus Lycii of the present invention and Auricularia composition granule comprises the steps: respectively to take by weighing Auricularia and Fructus Lycii at 1: 1 and with its pulverizing according to weight ratio, decoct with water 3 times, adding for the first time 20 times of water gagings decocted 2-4 hour, adding for the second time 15 times of water gagings decocted 1-3 hour, add 10 times of water gagings for the third time and decocted collecting decoction 1 hour; The decocting liquid concentrating under reduced pressure is become thick extractum, and, pulverize, cross 100 mesh sieves at 70 ℃ of drying under reduced pressure; Then add an amount of 10% polyvidone alcoholic solution, mixing is made soft material, crosses 12 mesh sieves and makes soft granule; Soft granule is passed through 12 mesh sieves once more after 60 ℃ of following dryings, granulate, total mixing, packing promptly makes Fructus Lycii and Auricularia granule (to call Qi ear granule in the following text).
Give rats gavaged with the fat milk of fat, cholesterol, sodium cholate and propylthiouracil preparation among the present invention embodiment subsequently, the preparation fatty liver model is studied the lipotropy of Fructus Lycii and Auricularia.Experimental result discloses, and Fructus Lycii and Auricularia have tangible lipotropy, and liver weight/Body Mass Index is reduced, and serum regulating liver-QI tissue cholesterol content descends, the hepatocyte number of steatosis reduces.Fructus Lycii and Auricularia can be used for preparing lipotropic preparation.
Description of drawings
Fig. 1 is normal group normal liver tissue observed result figure (HE dyeing * 200) under HE dyeing mirror;
Fig. 2 is the serious steatosis of model group hepatocyte observed result figure (HE dyeing * 200) under HE dyeing mirror;
Fig. 3 is the heavy dose of group of Qi ear granule observed result figure (HE dyeing * 200) under HE dyeing mirror;
Fig. 4 is dosage group observed result figure (HE dyeing * 200) under HE dyeing mirror in the Qi ear granule;
Fig. 5 is Qi ear granule small dose group observed result figure (HE dyeing * 200) under HE dyeing mirror;
Positive group of liver organization of Fig. 6 be observed result figure (HE dyeing * 200) under HE dyeing mirror;
Fig. 7 is observed result figure under the normal group collagen staining mirror (a small amount of collagen is seen in collagen staining * 200, portal area);
Fig. 8 is observed result figure under the model group collagen staining mirror (collagen staining * 200, portal area have collagen to stretch to the tissue edge);
Fig. 9 is observed result figure (a small amount of collagen is seen in collagen staining * 200, portal area) under the heavy dose of group of the Qi ear granule collagen staining mirror;
Figure 10 is observed result figure (a small amount of collagen is seen in collagen staining * 200, portal area) under the dosage group collagen staining mirror in the Qi ear granule;
Figure 11 is observed result figure (a small amount of collagen is seen in collagen staining * 200, portal area) under the Qi ear granule small dose group collagen staining mirror;
Observed result figure (a small amount of collagen is seen in collagen staining * 200, portal area) under positive group of collagen staining mirror of Figure 12.
The specific embodiment
Below in conjunction with drawings and Examples the present invention is described in further detail.
Fructus Lycii that following examples of the present invention are used and Auricularia are all purchased the great scape prepared slices of Chinese crude drugs company limited in Henan, all meet the relevant every regulation under each medical material item of text of Chinese Pharmacopoeia version in 2005.Each medical material has passed through processed such as clean system, cutting, the process of preparing Chinese medicine, pulverizing, before feeding intake, is tested and appraised, and each medical material material object of distinguishing the flavor of conforms to title, and quality meets state-promulgated pharmacopoeia standard (concrete medical material evaluation way is carried out with reference to standards of pharmacopoeia).
The used Qi ear granule of following examples of the present invention adopts following method to be prepared from: take by weighing Auricularia 1kg, Fructus Lycii 1kg, be ground into coarse powder, hot water decocts 3 times, and the 40L decocting boiled 3 hours for the first time, the 30L decocting boiled 2 hours for the second time, the 20L decocting boiled 1 hour for the third time, and decocting liquid merges, and concentrating under reduced pressure becomes thick extractum, 70 ℃ of drying under reduced pressure, pulverized 100 mesh sieves, and got Qi ear water extract, extracting yield is 25.2%; Get Qi ear water extract, add an amount of 10% polyvidone alcoholic solution, mixing is made soft material, crosses 12 mesh sieves and makes soft granule, and is dry under 60 ℃, by 12 mesh sieve granulate, and total mixing, packing promptly gets Qi ear granule.
The used experiment material of following examples of the present invention comprises:
1, animal:
96 of SD rats, male, every weight 180-220 gram is provided by Shanghai Univ. of Traditional Chinese Medicine zoopery center.
2, medicine:
Simvastatin, Jiangsu Lianhuan Pharmaceutical Co., Ltd., lot number: 2005901.
Propylthiouracil, Germany, lot number: 503330.
NaTDC, Shanghai traditional Chinese medicines chemical reagents corporation, lot number: F20031018.
Cholesterol, Shanghai traditional Chinese medicines chemical reagents corporation, lot number: F20041228.
Propylene glycol, Shanghai traditional Chinese medicines chemical reagents corporation, lot number: T20051207.
Tween 80, Shanghai traditional Chinese medicines chemical reagents corporation, lot number: F20050721.
The self-control refined lard.
3, main agents and instrument:
T-CHOL (TC), triglyceride (TG), famous classic bio tech ltd, lot number 20060324.
The high speed dispersion device, the Shanghai gold reaches biochemical instrument factory, specification: XHF-1
Refrigerated centrifuger, Anting Scientific Instrument Factory, Shanghai, specification: TGL-16G
Embodiment (anti-fatty liver experiment)
1.1 animal grouping:
According to table of random number it is divided into 6 groups:
1: the normal control group: 14+4
2: model control group: 15+5
3: simvastatin group (positive controls): 14
4: Qi ear granule group (heavy dose): 15
5: Qi ear granule group (middle dosage): 14
6: Qi ear granule group (low dose): 15
Normal control group and model control group altogether more reserves 9, and purpose is: after about modeling 4W, put to death the formation situation of observing the fatty liver model earlier, to determine formal modeling required time.
1.2 the preparation of modeling reagent:
Reference literature (Liu Ming etc.: a kind of simple and practical hyperlipemia model of rats. the Chinese Pharmacological magazine, 1985,20 (5): do suitably to adjust 199-199) and according to preliminary experiment and press legal system and be equipped with fat milk:
1: cholesterol 1/2 bottle (25g/ bottle) is ground into powder.Add the 25ml propylene glycol and the 25ml tween 80 stirs evenly.
2: 1/4 bottle of sodium cholate (10g/ bottle) is dissolved in the 50ml distilled water.
3: propylthiouracil 1/4 bottle (25) (50mg/ sheet, 100 slice/bottle) is ground into powder.Be added in the good sodium cholate bottle of dissolving and shake up.
4: refined lard 37.5g put beaker in hot water, fully be melted up to transparent after, be added in the cholesterol of handling well and stir evenly.
5: the sodium cholate and the propylthiouracil that will be dissolved in together are added in the cholesterol that is dissolved in together and the refined lard and stir evenly.
6: at last above-mentioned emulsion is settled to 250ml.
(annotate: under each composition ratio and concentration permanence condition, can prepare the fat milk of suitable capacity as required.Irrigation stomach device is that No. 20 syringe needle are made.)
1.3 modeling medication: be 2ml/100g.d and irritate stomach.
1.4 medication: it is 0.166g/ml, 0.084g/ml, 0.042g/ml that Qi ear granule is mixed with concentration respectively.Simvastatin is mixed with 0.4mg/ml.About morning every day is during 9:00, irritate Qi ear granule or the simvastatin medicinal liquid 1ml/100g.d that stomach gives variable concentrations respectively, (make the dosage of the large, medium and small dosage group of Qi ear granule be respectively 1.66g/kg, 0.84g/kg, 0.42g/kg, the dosage of simvastatin is 4mg/kg) matched group waits the normal saline of capacity; Irritate stomach about during 1:00 and give fat milk afternoon every day.Raise routinely and normal feeding feedwater, successive administration and modeling are about 30 days.
1.5 detect index and method:
1.5.1 influence: observe rat appetite every day, behavior, state to the rat ordinary circumstance.Weigh once weekly.Whether successive administration and modeling are afterwards handled several animals observation fatty livers earlier and are formed about 30 days.Treat to put to death simultaneously after fatty liver forms and respectively organize rat and descend the example observation.Put to death rat fasting 12h, and survey body weight.
1.5.2 blood biochemical detects: rat aorta is got blood, and 3000rpm centrifugalize serum is standby, press the content of test kit description mensuration TC, TG and ALT, AST activity.
1.5.3 liver tissue homogenate's biochemistry detection: get liver and weigh, and the fresh liver tissue 0.5g that will take from same position is in the ice normal saline after the rinsing, put in the 10ml centrifuge tube that fills 4.5ml 0.86% ice normal saline, homogenate in 10 seconds/time in ice-water bath, the homogenate of preparation 10%, the centrifuging and taking supernatant is pressed content that the test kit description measures TC, TG and ALT, AST activity.
1.5.4 liver organization morphological examination: the hepatic tissue that other gets each same position of rat is dipped in 10% the formalin solution fixing, paraffin embedding, section, HE dyeing.Microscopically is observed the steatosis degree of hepatic tissue.The liver slice collagen staining is observed the fibrosis lesion degree.
1.5.5 statistical method: continuous data is with mean ± standard deviation (x ± s) expression.Adopt the SPSS13.0 statistical software to carry out data analysis, relatively use one factor analysis of variance between many groups, relatively check between the group in twos with q; Ranked data are analyzed with nonparametric rank test (H check).
2, experimental result
2.1 ordinary circumstance: in the experiment, it is yellow that the model group animal skin becomes, the fluffy and disorderly cunning that has some setbacks, lassitude, animal no significant difference between other each groups.
2.2 to the exponential influence of liver: behind the rat oral gavage 4W, model group liver index is than the obvious rising of normal group, and difference has statistical significance (P＜0.05); Qi ear granule group (heavy dose) liver index is than the remarkable reduction of model group, and difference has statistical significance (P＜0.05) to the results are shown in Table 1.
Table 1. Qi ear granule is to the exponential influence of fatty liver rats'liver (X ± SD)
*P≤0.05vs model control group
2.3 blood biochemical testing result
2.3.1 influence to serum TC content
Compare with normal group, the content of TC obviously raises in the model group rat blood serum, and the content of TC is all than the remarkable reduction of model group in Qi ear granule group (big-and-middle dosage) serum, and difference has statistical significance (P＜0.05) to the results are shown in Table 2.
Table 2 Qi ear granule is to the influence of TC content in the fatty liver rat blood serum (X ± SD)
*P＜0.05vs model control group
2.3.2 influence to TG content in the serum
Table 3 shows that animal pattern serum TG concentration does not raise, and the concentration of TG in the serum is not had by reagent yet and acts on.The results are shown in Table 3
Table 3 Qi ear granule is to the influence of TG content in the fatty liver rat blood serum (X ± SD)
2.4 the result of liver tissue homogenate's biochemistry detection
2.4.1 influence to hepatic tissue TC content
Compare with normal group, TC content obviously raises in the model group liver tissues of rats, and the content of TC is all than the remarkable reduction of model group in Qi ear granule group (large, medium and small dosage) and the positive group hepatic tissue, and difference has statistical significance (P＜0.05) to the results are shown in Table 4.
Table 4. Qi ear granule is to the influence of TC content in the fatty liver liver tissues of rats (X ± SD)
*P≤0.05vs model control group
2.5 the hepatopathy result who checks of science
2.5.1 outward appearance and pathological examination
Normal group, most rat liver perusal is cerise, clear-cut margin, smooth surface in positive group and the Qi ear granule.The rat liver volume of fraction increases in model and the Qi ear granule, and marginal edge is blunt, its colour changed into yellow, visible surface white dot, tangent plane greasy feeling.
2.5.2HE observed result under the dyeing mirror
The hepatic tissue HE dyeing back normal rats lobules of liver at the same position of rat is complete, hepatocyte is polygon and is radial around central vein, accidental hepatic cell fattydegeneration, do not see inflammatory cell infiltration, sinus hepaticus is high-visible, liver bundle marshalling, lobules of liver portal area basic structure comprise that interlobular bile duct, interlobular arteries, interlobular veins are high-visible.Model group rat hepatocytes diffusivity steatosis, the swelling of hepatocyte moderate is cavity shape and cystose, in the lobule of portal area cell infiltration is arranged, and inflammatory cell is based on mononuclear cell, lymphocyte.Spotty necrosis, the necrosis of kitchen range shape appear in part.The most of hepatocyte of Qi ear granule group is tending towards normally, rarely seen a small amount of focal slight hepatic cell fattydegeneration, and the fraction visible inflammatory cell soaks into.Compare with normal group, model group u value has remarkable statistical significance (P＜0.01) less than the normal group difference.Positive group and the heavy dose of group of Qi ear granule u value are greater than model group, and difference has statistical significance (P＜0.05).Qi ear granule small dose group u value is greater than model group, and difference has remarkable statistical significance (P＜0.01).The pathological change of the big or middle dosage group of Qi ear granule alleviates, but not remarkable with the model group comparing difference.The results are shown in Table 5 and Fig. 1-6 shown in.
Table 5 Qi ear granule anti-fatty liver research pathological data
The hepatocyte of (-) fat-free degeneration
The hepatocyte of (±) steatosis accounts for lobules of liver＜1/5
The hepatocyte of (+) steatosis accounts for lobules of liver 1/5-2/5
The hepatocyte of (++) steatosis accounts for lobules of liver 2/5-3/5
The hepatocyte of (+++) steatosis accounts for lobules of liver＞3/5
According to rank test:
Normal control group vs model control group u=4.0395＞2.58P＜0.01
Simvastatin group vs model control group u=1.9975＞1.96P＜0.05
The heavy dose of group of Qi ear granule vs model control group u=2.0028＞1.96P＜0.05
Dosage group vs model control group u=1.6426＜1.96P＞0.05 in the Qi ear granule
Qi ear granule small dose group vs model control group u=2.5931＞2.58P＜0.01
2.5.3 observed result under the collagen staining mirror
Shown in Fig. 7-12, the visible obvious thick red collagen fiber of model group collagen staining are distributed in portal area and the central vein tube wall, and the portal area has a small amount of collagen to stretch to the tissue edge, and the fibrous septum is mainly dyed and is reddish yellow between the imperfection header.Normal group red color visible collagen fiber mainly are distributed in portal area and the central vein tube wall.Compare with normal group, red collagen fiber are obviously more than normal group in the model group, and Qi ear granule and positive group red color visible collagen fiber quantity obviously are less than model group.
The Qi ear granule that the above embodiment of the present invention adopts is to process extraction with two kinds of Chinese medicines, and wherein a kind of is Auricularia.Existing Auricularia polycose cholesterol reducing effect research report in the prior art, method is: give the rat high lipid food 1 week, set up hyperlipemia model, with Auricularia polycose the rat of tool hyperlipemia is carried out muscle of thigh and injected for 1 week, dosage is 15mg/kg d every day, measures total cholesterol level in the serum.The result injects that the total cholesterol level of rat has reduced by 42.2% than matched group behind the Auricularia polycose, effect significantly be Auricularia polycose have significant cholesterol reducing effect (Cai Xiaoling etc. the cholesterol reducing effect of Auricularia polycose research. Shenzhen combination of Chinese and Western medicine magazine, 2002,5 (3): 170-172).The Qi ear granule that the above embodiment of the present invention adopts is the Chinese medicine extraction gained from two kinds of medicine-food two-purposes, adopts the approach of oral administration, and the clinical Qi ear granule that gives of experimental result explanation has the effect that reduces the hepatic tissue cholesterol level.General documents and materials are thought: the formation major part of fatty liver is that institute causes because cholesterol raises, therefore the results suggest of the embodiment of the invention this be subjected to reagent certain preventive and therapeutic effect should be arranged to this class fatty liver that causes that raises because of cholesterol is long-term, it can be developed to lipotropic medicine.But Qi ear granule there is no tangible improvement effect to the rising of triglyceride, so may be invalid to the patient of triglyceride rising clinically.
Claims (4)
1. Fructus Lycii and the Auricularia application in preparation anti-fatty liver medicine.
2. purposes according to claim 1 is characterized in that, Fructus Lycii is the dry mature fruit of plant of Solanaceae lycium barbarum Lycium barbarum L.; Auricularia is mushroom food Auriculariaauricular-judae.
3. purposes according to claim 1 and 2 is characterized in that Fructus Lycii and Auricularia use the granule of its compositions.
4. purposes according to claim 3 is characterized in that, Fructus Lycii and Auricularia composition granule using dosage be 1-30g/ days/become human oral, be equivalent to oral Fructus Lycii, Auricularia 4-120g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710038186XA CN101269152A (en) | 2007-03-19 | 2007-03-19 | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710038186XA CN101269152A (en) | 2007-03-19 | 2007-03-19 | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101269152A true CN101269152A (en) | 2008-09-24 |
Family
ID=40003543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200710038186XA Pending CN101269152A (en) | 2007-03-19 | 2007-03-19 | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101269152A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103141832A (en) * | 2013-02-04 | 2013-06-12 | 杭州方回春堂国药馆有限公司 | Black fungus diet therapy health-preserving diet and preparation method thereof |
| CN105495261A (en) * | 2015-12-07 | 2016-04-20 | 刘可 | Black fungus beverage granules for preventing fatty liver, and preparation method and application thereof |
| CN105533384A (en) * | 2015-12-07 | 2016-05-04 | 刘可 | Black fungus beverage granules preventing fatty liver and preparation method and application thereof |
-
2007
- 2007-03-19 CN CNA200710038186XA patent/CN101269152A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103141832A (en) * | 2013-02-04 | 2013-06-12 | 杭州方回春堂国药馆有限公司 | Black fungus diet therapy health-preserving diet and preparation method thereof |
| CN105495261A (en) * | 2015-12-07 | 2016-04-20 | 刘可 | Black fungus beverage granules for preventing fatty liver, and preparation method and application thereof |
| CN105533384A (en) * | 2015-12-07 | 2016-05-04 | 刘可 | Black fungus beverage granules preventing fatty liver and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101277710B (en) | Antiobesity composition | |
| CA2362934A1 (en) | Sugar imbalance and diabetes treating herbal formulation | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN105124078A (en) | Gardenia blood-glucose-reducing and lipid-reducing healthcare tea and preparing method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
| CN102697781A (en) | Application of trigonelline in preparation of medicament for preventing and treating diabetes and complication thereof | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
| CN101897925A (en) | Medicinal composition for treating metabolic syndrome | |
| CN107137420A (en) | A kind of mulberry leaf-chrysanthemum Chinese yam complex polysaccharide with clearing heat and nourishing yin function of blood sugar reduction and preparation method thereof | |
| CN101890073B (en) | Chinese medicinal composition for preventing and treating hyperlipaemia and fatty liver and preparation method thereof | |
| US20030232099A1 (en) | Health-care products and methods for preparing and using the same | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN100551396C (en) | A kind of Chinese patent medicine for the treatment of fatty liver and preparation method thereof | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN102920991B (en) | Application of composition of Chinese yarn polysaccharide and Chinese yarn protein | |
| CN102106993A (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN103041288B (en) | A kind of Chinese medicine composition and preparation technology treating diabetic fatty liver | |
| CN110507759A (en) | A kind of three yellow Chinese herbal preparation of particles and preparation method thereof with control hyperglycemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080924 |